Clinical trials: Multiple Sclerosis (Relapsing Remitting)
Relapsing Remitting Multiple Sclerosis
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01963611
- Testing
- Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg
- Where
- 118 sites in United States, Bulgaria and 15 more
- Volunteers
- 255 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis
Our project proposal is based on an individualized rehabilitation approach in patients with early stage relapsing remission (RR) MS.
- Trial name
- RELIABLE (NCT06303024)
- Testing
- personalized combined physical and cognitive intervention
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
This study is a randomized controlled trial (RCT) that compares the effects of two different 12-month aerobic walking exercise programs on cognitive processing speed (CPS), brain MRI, and other functional outcomes in 32 adults…
- Trial name
- NCT05755061
- Testing
- GEMS Plus, GEMS
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better.
- Trial name
- NCT06220669
- Testing
- LY3541860
- Where
- 20 sites in United States, France and 5 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis (MS) - Relapsing-remitting
Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)
This phase of the project aims to analyze the interaction between physical exercise and the phases of the menstrual cycle, evaluating its impact on fatigue, functional capacity, and exercise perception in women with and without…
- Trial name
- ADVICE Phase 1 (NCT06925022)
- Testing
- Strength training session during Early Follicular Phase, Strength Training Protocol during Late Follicular Phase, Strength Training during Mid-Luteal Phase
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidad de Almeria
Relapsing Remitting Multiple Sclerosis
A Study for Patients With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.
- Trial name
- MINDSET01 (NCT00869986)
- Testing
- dirucotide
- Where
- 6 sites in Bulgaria, Poland and 4 more
- Volunteers
- 218 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line…
- Trial name
- MESTRE-MS (NCT02949908)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine if high-dose cyclophosphamide followed by a maintenance dose of glatiramer acetate is safe in patients with relapsing remitting multiple sclerosis (MS).
- Trial name
- HiCy (NCT00939549)
- Testing
- Cyclophosphamide/Glatiramer acetate
- Where
- United States
- Sponsor
- Johns Hopkins University
Relapsing Remitting Multiple Sclerosis
Vitamin D Pilot Study in Patients With Multiple Sclerosis
Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.
- Trial name
- NCT01257958
- Testing
- 19 nor vitamin d
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- SONICS (NCT03942952)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Relapsing-Remitting
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
The main purpose of this study is to assess clemastine as a remyelinating agent in patients with relapsing forms of multiple sclerosis.
- Trial name
- ReBUILD (NCT02040298)
- Testing
- Clemastine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Based on favorable preliminary data from ongoing studies testing the safety and tolerability of a nutrition, exercise and neuromuscular electrical stimulation funded by Direct MS, the investigators are proposing a pilot study…
- Trial name
- NCT01915433
- Testing
- Wahls Paleo Plus, Wahls Diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Terry L. Wahls
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Relapsing Remitting Multiple Sclerosis
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone injections in all subjects.
- Trial name
- Estriol-MS (NCT00451204)
- Testing
- Estriol, Copaxone
- Where
- 16 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or…
- Trial name
- OMS115102 (NCT00640328)
- Testing
- Ofatumumab 100, Ofatumumab 300, Ofatumumab 700
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Patient Experiences of Multiple Sclerosis (PExMS)
Besides coping with the diagnosis, people with multiple sclerosis have to make complex decisions such as deciding about immunotherapies.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Patient Engagement, Self Efficacy
- Trial name
- PExMS (NCT04236544)
- Testing
- PExMS and DECIMS-Wiki, DECIMS-Wiki
- Volunteers
- 55 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute…
- Trial name
- NCT00349193
- Testing
- laquinimod 0.3, laquinimod 0.6
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Serum Neurofilament Light in Multiple Sclerosis
This prospective cohort study is designed to characterize the utility of sNfL as a biomarker in clinical practice. This study also aims to understand how access to sNfL measures affects patient and clinician knowledge of their…
- Trial name
- NCT06282081
- Testing
- Serum Neurofilament Light
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Dent Neuroscience Research Center
Relapsing Remitting Multiple Sclerosis
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- TYPIFI (NCT04832399)
- Testing
- Natalizumab
- Where
- 18 sites in Portugal
- Volunteers
- 60 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
- Trial name
- FREEDOMS (NCT00289978)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg
- Where
- 115 sites in Australia, Belgium and 17 more
- Volunteers
- 1,272 people
- Sponsor
- Novartis